A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae

BMC Infectious Diseases

Kailey Berry¹  Madison Tipton¹  Jared Haberman¹  Tracy L. Webb²  Elizabeth P. Ryan³  Bridget A. Baxter³  Stephanie M. LaVergne³  Sophia Stromberg⁴  Gregory D. Ebel⁵  Marcela Henao-Tamayo⁵  Taru S. Dutt⁵  Benjamin R. Massey⁶  Thomas Heacock⁷  Linda Zier⁷  Omar Alnachoukati⁷  Kim McFann⁷  Julie Dunn⁷ 

[1] Department of Biomedical Sciences, Colorado State University;Department of Clinical Sciences, Colorado State University;Department of Environmental and Radiological Health Sciences, Colorado State University;Department of Food Science and Human Nutrition, Colorado State University;Department of Microbiology, Immunology and Pathology, Colorado State University;University of Colorado Anschutz School of Medicine;University of Colorado Health, Medical Center of the Rockies;

关键词: SARS-CoV-2;    COVID-19;    Post-acute sequelae of COVID-19 (PASC);    Long-hauler;    Biobank;    Biorepository;   

DOI  :  10.1186/s12879-021-06359-2

来源: DOAJ

【 摘 要 】

Abstract Background SARS-CoV-2 has swept across the globe, causing millions of deaths worldwide. Though most survive, many experience symptoms of COVID-19 for months after acute infection. Successful prevention and treatment of acute COVID-19 infection and its associated sequelae is dependent on in-depth knowledge of viral pathology across the spectrum of patient phenotypes and physiologic responses. Longitudinal biobanking provides a valuable resource of clinically integrated, easily accessed, and quality-controlled samples for researchers to study differential multi-organ system responses to SARS-CoV-2 infection, post-acute sequelae of COVID-19 (PASC), and vaccination. Methods Adults with a history of a positive SARS-CoV-2 nasopharyngeal PCR are actively recruited from the community or hospital settings to enroll in the Northern Colorado SARS-CoV-2 Biorepository (NoCo-COBIO). Blood, saliva, stool, nasopharyngeal specimens, and extensive clinical and demographic data are collected at 4 time points over 6 months. Patients are assessed for PASC during longitudinal follow-up by physician led symptom questionnaires and physical exams. This clinical trial registration is NCT04603677 . Results We have enrolled and collected samples from 119 adults since July 2020, with 66% follow-up rate. Forty-nine percent of participants assessed with a symptom surveillance questionnaire (N = 37 of 75) had PASC at any time during follow-up (up to 8 months post infection). Ninety-three percent of hospitalized participants developed PASC, while 23% of those not requiring hospitalization developed PASC. At 90–174 days post SARS-CoV-2 diagnosis, 67% of all participants had persistent symptoms (N = 37 of 55), and 85% percent of participants who required hospitalization during initial infection (N = 20) still had symptoms. The most common symptoms reported after 15 days of infection were fatigue, loss of smell, loss of taste, exercise intolerance, and cognitive dysfunction. Conclusions Patients who were hospitalized for COVID-19 were significantly more likely to have PASC than those not requiring hospitalization, however 23% of patients who were not hospitalized also developed PASC. This patient-matched, multi-matrix, longitudinal biorepository from COVID-19 survivors with and without PASC will allow for current and future research to better understand the pathophysiology of disease and to identify targeted interventions to reduce risk for PASC. Registered 27 October 2020 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04603677 .

【 授权许可】

Unknown